Loading…
Anti-inflammatory and proapoptotic effects of umbelliferone in colon carcinogenesis
Colorectal cancer (CRC) is a serious health problem throughout the world. 5-Flurouracil, the first-line chemotherapy of colorectal cancer often produces more toxicity to neighboring cells; however, it is still used for CRC treatment. To overcome this, umbelliferone (UMB), a less toxic bioflavonoid h...
Saved in:
| Published in: | Human & experimental toxicology 2016-10, Vol.35 (10), p.1041-1054 |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Request full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c398t-3425001fae9e5a7f5674dc7cc6868061f9fa0217ca2304aa4b8ff2205a37ff1e3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c398t-3425001fae9e5a7f5674dc7cc6868061f9fa0217ca2304aa4b8ff2205a37ff1e3 |
| container_end_page | 1054 |
| container_issue | 10 |
| container_start_page | 1041 |
| container_title | Human & experimental toxicology |
| container_volume | 35 |
| creator | Muthu, R Selvaraj, N Vaiyapuri, M |
| description | Colorectal cancer (CRC) is a serious health problem throughout the world. 5-Flurouracil, the first-line chemotherapy of colorectal cancer often produces more toxicity to neighboring cells; however, it is still used for CRC treatment. To overcome this, umbelliferone (UMB), a less toxic bioflavonoid has been used to test its anticancer effects on animal model. The objective of the present study is to evaluate the anticancer activity of UMB on 1,2-dimethylhydrazine (DMH)-induced rat colon tumorigenesis to determine the development of aberrant crypt foci (ACF), agyrophylic nucleolar organizer regions (AgNORs), mast cell recruitment, pro-inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1β and also study the expressions of inducible nitric oxide synthase, cyclooxygenase (COX)-2, and apoptotic markers. DMH-induced rats showed increased ACF number (incidence), multiplicity and its distribution, counts of AgNORs, mast cells, inflammatory markers and apoptotic proteins. Interestingly, UMB supplementation to DMH-induced rats (group 4) significantly (p < 0.05) suppressed ACF development, AgNORs, mast cells, and inflammatory markers and increased the apoptotic markers as compared to DMH-induced rats (group 2). We concluded that UMB is a potential anticancer agent that can be used for the prevention and treatment of CRC. |
| doi_str_mv | 10.1177/0960327115618245 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_AFRWT</sourceid><recordid>TN_cdi_proquest_miscellaneous_1827913539</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_0960327115618245</sage_id><sourcerecordid>1827913539</sourcerecordid><originalsourceid>FETCH-LOGICAL-c398t-3425001fae9e5a7f5674dc7cc6868061f9fa0217ca2304aa4b8ff2205a37ff1e3</originalsourceid><addsrcrecordid>eNp1kM1LAzEQxYMotlbvnmTBi5fVTLJJNsdS_IKCB_W8pGlSUnaTmuwe-t-b0ipS8DJzmN9783gIXQO-BxDiAUuOKREAjENNKnaCxlAJUWKJ6Ska787l7j5CFymtMcZcMjhHI8I5Y5yKMXqf-t6VzttWdZ3qQ9wWyi-LTQxqEzZ96J0ujLVG96kIthi6hWlbZ00M3hTOFzq0IU8VtfNhZbxJLl2iM6vaZK4Oe4I-nx4_Zi_l_O35dTadl5rKui9pRRjGYJWRhilhGRfVUgutec1rzMFKqzABoRWhuFKqWtTWEoKZosJaMHSC7va-Oe3XYFLfdC7pnE95E4bU5EqEBMqozOjtEboOQ_Q5XQMSCKGk5iJTeE_pGFKKxjab6DoVtw3gZld4c1x4ltwcjIdFZ5a_gp-GM1DugaRW5s_X_wy_AZnvh7M</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1912232867</pqid></control><display><type>article</type><title>Anti-inflammatory and proapoptotic effects of umbelliferone in colon carcinogenesis</title><source>SAGE Open Access Journals</source><creator>Muthu, R ; Selvaraj, N ; Vaiyapuri, M</creator><creatorcontrib>Muthu, R ; Selvaraj, N ; Vaiyapuri, M</creatorcontrib><description>Colorectal cancer (CRC) is a serious health problem throughout the world. 5-Flurouracil, the first-line chemotherapy of colorectal cancer often produces more toxicity to neighboring cells; however, it is still used for CRC treatment. To overcome this, umbelliferone (UMB), a less toxic bioflavonoid has been used to test its anticancer effects on animal model. The objective of the present study is to evaluate the anticancer activity of UMB on 1,2-dimethylhydrazine (DMH)-induced rat colon tumorigenesis to determine the development of aberrant crypt foci (ACF), agyrophylic nucleolar organizer regions (AgNORs), mast cell recruitment, pro-inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1β and also study the expressions of inducible nitric oxide synthase, cyclooxygenase (COX)-2, and apoptotic markers. DMH-induced rats showed increased ACF number (incidence), multiplicity and its distribution, counts of AgNORs, mast cells, inflammatory markers and apoptotic proteins. Interestingly, UMB supplementation to DMH-induced rats (group 4) significantly (p < 0.05) suppressed ACF development, AgNORs, mast cells, and inflammatory markers and increased the apoptotic markers as compared to DMH-induced rats (group 2). We concluded that UMB is a potential anticancer agent that can be used for the prevention and treatment of CRC.</description><identifier>ISSN: 0960-3271</identifier><identifier>EISSN: 1477-0903</identifier><identifier>DOI: 10.1177/0960327115618245</identifier><identifier>PMID: 26655637</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>1,2-Dimethylhydrazine ; 1,2-Dimethylhydrazine - toxicity ; Aberrant Crypt Foci - drug therapy ; Aberrant Crypt Foci - metabolism ; Aberrant Crypt Foci - pathology ; Aberration ; Animals ; Anti-Inflammatory Agents - administration & dosage ; Anti-Inflammatory Agents - therapeutic use ; Anticancer properties ; Antigens, Nuclear - metabolism ; Antineoplastic Agents, Phytogenic - administration & dosage ; Antineoplastic Agents, Phytogenic - therapeutic use ; Antitumor activity ; Apoptosis ; Apoptosis - drug effects ; Cancer ; Carcinogenesis ; Carcinogens ; Chemotherapy ; Colon ; Colon cancer ; Colonic Neoplasms - drug therapy ; Colonic Neoplasms - metabolism ; Colonic Neoplasms - pathology ; Colorectal cancer ; Colorectal carcinoma ; Cyclooxygenase-2 ; Cytokines ; Cytokines - metabolism ; Group dynamics ; IL-1β ; Incidence ; Inflammation ; Interleukins ; Male ; Markers ; Mast cells ; Mast Cells - drug effects ; Mast Cells - pathology ; Nitric oxide ; Nitric-oxide synthase ; Nucleoli ; Proteins ; Rats ; Rats, Wistar ; Recruitment ; Rodents ; Supplements ; Toxicity ; Tumor necrosis factor ; Tumor necrosis factor-TNF ; Tumorigenesis ; Umbelliferone ; Umbelliferones - administration & dosage ; Umbelliferones - therapeutic use</subject><ispartof>Human & experimental toxicology, 2016-10, Vol.35 (10), p.1041-1054</ispartof><rights>The Author(s) 2015</rights><rights>The Author(s) 2015.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c398t-3425001fae9e5a7f5674dc7cc6868061f9fa0217ca2304aa4b8ff2205a37ff1e3</citedby><cites>FETCH-LOGICAL-c398t-3425001fae9e5a7f5674dc7cc6868061f9fa0217ca2304aa4b8ff2205a37ff1e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/0960327115618245$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/0960327115618245$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21966,27853,27924,27925,44945,45333</link.rule.ids><linktorsrc>$$Uhttps://journals.sagepub.com/doi/full/10.1177/0960327115618245?utm_source=summon&utm_medium=discovery-provider$$EView_record_in_SAGE_Publications$$FView_record_in_$$GSAGE_Publications</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26655637$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Muthu, R</creatorcontrib><creatorcontrib>Selvaraj, N</creatorcontrib><creatorcontrib>Vaiyapuri, M</creatorcontrib><title>Anti-inflammatory and proapoptotic effects of umbelliferone in colon carcinogenesis</title><title>Human & experimental toxicology</title><addtitle>Hum Exp Toxicol</addtitle><description>Colorectal cancer (CRC) is a serious health problem throughout the world. 5-Flurouracil, the first-line chemotherapy of colorectal cancer often produces more toxicity to neighboring cells; however, it is still used for CRC treatment. To overcome this, umbelliferone (UMB), a less toxic bioflavonoid has been used to test its anticancer effects on animal model. The objective of the present study is to evaluate the anticancer activity of UMB on 1,2-dimethylhydrazine (DMH)-induced rat colon tumorigenesis to determine the development of aberrant crypt foci (ACF), agyrophylic nucleolar organizer regions (AgNORs), mast cell recruitment, pro-inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1β and also study the expressions of inducible nitric oxide synthase, cyclooxygenase (COX)-2, and apoptotic markers. DMH-induced rats showed increased ACF number (incidence), multiplicity and its distribution, counts of AgNORs, mast cells, inflammatory markers and apoptotic proteins. Interestingly, UMB supplementation to DMH-induced rats (group 4) significantly (p < 0.05) suppressed ACF development, AgNORs, mast cells, and inflammatory markers and increased the apoptotic markers as compared to DMH-induced rats (group 2). We concluded that UMB is a potential anticancer agent that can be used for the prevention and treatment of CRC.</description><subject>1,2-Dimethylhydrazine</subject><subject>1,2-Dimethylhydrazine - toxicity</subject><subject>Aberrant Crypt Foci - drug therapy</subject><subject>Aberrant Crypt Foci - metabolism</subject><subject>Aberrant Crypt Foci - pathology</subject><subject>Aberration</subject><subject>Animals</subject><subject>Anti-Inflammatory Agents - administration & dosage</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Anticancer properties</subject><subject>Antigens, Nuclear - metabolism</subject><subject>Antineoplastic Agents, Phytogenic - administration & dosage</subject><subject>Antineoplastic Agents, Phytogenic - therapeutic use</subject><subject>Antitumor activity</subject><subject>Apoptosis</subject><subject>Apoptosis - drug effects</subject><subject>Cancer</subject><subject>Carcinogenesis</subject><subject>Carcinogens</subject><subject>Chemotherapy</subject><subject>Colon</subject><subject>Colon cancer</subject><subject>Colonic Neoplasms - drug therapy</subject><subject>Colonic Neoplasms - metabolism</subject><subject>Colonic Neoplasms - pathology</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Cyclooxygenase-2</subject><subject>Cytokines</subject><subject>Cytokines - metabolism</subject><subject>Group dynamics</subject><subject>IL-1β</subject><subject>Incidence</subject><subject>Inflammation</subject><subject>Interleukins</subject><subject>Male</subject><subject>Markers</subject><subject>Mast cells</subject><subject>Mast Cells - drug effects</subject><subject>Mast Cells - pathology</subject><subject>Nitric oxide</subject><subject>Nitric-oxide synthase</subject><subject>Nucleoli</subject><subject>Proteins</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Recruitment</subject><subject>Rodents</subject><subject>Supplements</subject><subject>Toxicity</subject><subject>Tumor necrosis factor</subject><subject>Tumor necrosis factor-TNF</subject><subject>Tumorigenesis</subject><subject>Umbelliferone</subject><subject>Umbelliferones - administration & dosage</subject><subject>Umbelliferones - therapeutic use</subject><issn>0960-3271</issn><issn>1477-0903</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNp1kM1LAzEQxYMotlbvnmTBi5fVTLJJNsdS_IKCB_W8pGlSUnaTmuwe-t-b0ipS8DJzmN9783gIXQO-BxDiAUuOKREAjENNKnaCxlAJUWKJ6Ska787l7j5CFymtMcZcMjhHI8I5Y5yKMXqf-t6VzttWdZ3qQ9wWyi-LTQxqEzZ96J0ujLVG96kIthi6hWlbZ00M3hTOFzq0IU8VtfNhZbxJLl2iM6vaZK4Oe4I-nx4_Zi_l_O35dTadl5rKui9pRRjGYJWRhilhGRfVUgutec1rzMFKqzABoRWhuFKqWtTWEoKZosJaMHSC7va-Oe3XYFLfdC7pnE95E4bU5EqEBMqozOjtEboOQ_Q5XQMSCKGk5iJTeE_pGFKKxjab6DoVtw3gZld4c1x4ltwcjIdFZ5a_gp-GM1DugaRW5s_X_wy_AZnvh7M</recordid><startdate>201610</startdate><enddate>201610</enddate><creator>Muthu, R</creator><creator>Selvaraj, N</creator><creator>Vaiyapuri, M</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7ST</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>SOI</scope></search><sort><creationdate>201610</creationdate><title>Anti-inflammatory and proapoptotic effects of umbelliferone in colon carcinogenesis</title><author>Muthu, R ; Selvaraj, N ; Vaiyapuri, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c398t-3425001fae9e5a7f5674dc7cc6868061f9fa0217ca2304aa4b8ff2205a37ff1e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>1,2-Dimethylhydrazine</topic><topic>1,2-Dimethylhydrazine - toxicity</topic><topic>Aberrant Crypt Foci - drug therapy</topic><topic>Aberrant Crypt Foci - metabolism</topic><topic>Aberrant Crypt Foci - pathology</topic><topic>Aberration</topic><topic>Animals</topic><topic>Anti-Inflammatory Agents - administration & dosage</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Anticancer properties</topic><topic>Antigens, Nuclear - metabolism</topic><topic>Antineoplastic Agents, Phytogenic - administration & dosage</topic><topic>Antineoplastic Agents, Phytogenic - therapeutic use</topic><topic>Antitumor activity</topic><topic>Apoptosis</topic><topic>Apoptosis - drug effects</topic><topic>Cancer</topic><topic>Carcinogenesis</topic><topic>Carcinogens</topic><topic>Chemotherapy</topic><topic>Colon</topic><topic>Colon cancer</topic><topic>Colonic Neoplasms - drug therapy</topic><topic>Colonic Neoplasms - metabolism</topic><topic>Colonic Neoplasms - pathology</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Cyclooxygenase-2</topic><topic>Cytokines</topic><topic>Cytokines - metabolism</topic><topic>Group dynamics</topic><topic>IL-1β</topic><topic>Incidence</topic><topic>Inflammation</topic><topic>Interleukins</topic><topic>Male</topic><topic>Markers</topic><topic>Mast cells</topic><topic>Mast Cells - drug effects</topic><topic>Mast Cells - pathology</topic><topic>Nitric oxide</topic><topic>Nitric-oxide synthase</topic><topic>Nucleoli</topic><topic>Proteins</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Recruitment</topic><topic>Rodents</topic><topic>Supplements</topic><topic>Toxicity</topic><topic>Tumor necrosis factor</topic><topic>Tumor necrosis factor-TNF</topic><topic>Tumorigenesis</topic><topic>Umbelliferone</topic><topic>Umbelliferones - administration & dosage</topic><topic>Umbelliferones - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Muthu, R</creatorcontrib><creatorcontrib>Selvaraj, N</creatorcontrib><creatorcontrib>Vaiyapuri, M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Environment Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Environment Abstracts</collection><jtitle>Human & experimental toxicology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Muthu, R</au><au>Selvaraj, N</au><au>Vaiyapuri, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-inflammatory and proapoptotic effects of umbelliferone in colon carcinogenesis</atitle><jtitle>Human & experimental toxicology</jtitle><addtitle>Hum Exp Toxicol</addtitle><date>2016-10</date><risdate>2016</risdate><volume>35</volume><issue>10</issue><spage>1041</spage><epage>1054</epage><pages>1041-1054</pages><issn>0960-3271</issn><eissn>1477-0903</eissn><abstract>Colorectal cancer (CRC) is a serious health problem throughout the world. 5-Flurouracil, the first-line chemotherapy of colorectal cancer often produces more toxicity to neighboring cells; however, it is still used for CRC treatment. To overcome this, umbelliferone (UMB), a less toxic bioflavonoid has been used to test its anticancer effects on animal model. The objective of the present study is to evaluate the anticancer activity of UMB on 1,2-dimethylhydrazine (DMH)-induced rat colon tumorigenesis to determine the development of aberrant crypt foci (ACF), agyrophylic nucleolar organizer regions (AgNORs), mast cell recruitment, pro-inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1β and also study the expressions of inducible nitric oxide synthase, cyclooxygenase (COX)-2, and apoptotic markers. DMH-induced rats showed increased ACF number (incidence), multiplicity and its distribution, counts of AgNORs, mast cells, inflammatory markers and apoptotic proteins. Interestingly, UMB supplementation to DMH-induced rats (group 4) significantly (p < 0.05) suppressed ACF development, AgNORs, mast cells, and inflammatory markers and increased the apoptotic markers as compared to DMH-induced rats (group 2). We concluded that UMB is a potential anticancer agent that can be used for the prevention and treatment of CRC.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>26655637</pmid><doi>10.1177/0960327115618245</doi><tpages>14</tpages></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | ISSN: 0960-3271 |
| ispartof | Human & experimental toxicology, 2016-10, Vol.35 (10), p.1041-1054 |
| issn | 0960-3271 1477-0903 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1827913539 |
| source | SAGE Open Access Journals |
| subjects | 1,2-Dimethylhydrazine 1,2-Dimethylhydrazine - toxicity Aberrant Crypt Foci - drug therapy Aberrant Crypt Foci - metabolism Aberrant Crypt Foci - pathology Aberration Animals Anti-Inflammatory Agents - administration & dosage Anti-Inflammatory Agents - therapeutic use Anticancer properties Antigens, Nuclear - metabolism Antineoplastic Agents, Phytogenic - administration & dosage Antineoplastic Agents, Phytogenic - therapeutic use Antitumor activity Apoptosis Apoptosis - drug effects Cancer Carcinogenesis Carcinogens Chemotherapy Colon Colon cancer Colonic Neoplasms - drug therapy Colonic Neoplasms - metabolism Colonic Neoplasms - pathology Colorectal cancer Colorectal carcinoma Cyclooxygenase-2 Cytokines Cytokines - metabolism Group dynamics IL-1β Incidence Inflammation Interleukins Male Markers Mast cells Mast Cells - drug effects Mast Cells - pathology Nitric oxide Nitric-oxide synthase Nucleoli Proteins Rats Rats, Wistar Recruitment Rodents Supplements Toxicity Tumor necrosis factor Tumor necrosis factor-TNF Tumorigenesis Umbelliferone Umbelliferones - administration & dosage Umbelliferones - therapeutic use |
| title | Anti-inflammatory and proapoptotic effects of umbelliferone in colon carcinogenesis |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T05%3A55%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_AFRWT&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-inflammatory%20and%20proapoptotic%20effects%20of%20umbelliferone%20in%20colon%20carcinogenesis&rft.jtitle=Human%20&%20experimental%20toxicology&rft.au=Muthu,%20R&rft.date=2016-10&rft.volume=35&rft.issue=10&rft.spage=1041&rft.epage=1054&rft.pages=1041-1054&rft.issn=0960-3271&rft.eissn=1477-0903&rft_id=info:doi/10.1177/0960327115618245&rft_dat=%3Cproquest_AFRWT%3E1827913539%3C/proquest_AFRWT%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c398t-3425001fae9e5a7f5674dc7cc6868061f9fa0217ca2304aa4b8ff2205a37ff1e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1912232867&rft_id=info:pmid/26655637&rft_sage_id=10.1177_0960327115618245&rfr_iscdi=true |